**Gynura procumbens** Extract Alleviates Postprandial Hyperglycemia in Diabetic Mice

Sung-In Choi¹, Mi Hwa Park², and Ji-Sook Han¹

¹Department of Food Science and Nutrition, Pusan National University, Busan 46241, Korea
²Department of Food and Nutrition, College of Medical and Life Science, Silla University, Busan 46958, Korea

**ABSTRACT:** This study was designed to investigate the inhibitory effect of *Gynura procumbens* extract against carbohydrate digesting enzymes and its ability to ameliorate postprandial hyperglycemia in streptozotocin (STZ)-induced diabetic mice. *G. procumbens* extract showed prominent α-glucosidase and α-amylase inhibitory effects. The half-maximal inhibitory concentration (IC₅₀) of *G. procumbens* extract against α-glucosidase and α-amylase was 0.092±0.018 and 0.084±0.027 mg/mL, respectively, suggesting that the α-amylase inhibition activity of the *G. procumbens* extract was more effective than that of the positive control, acarbose (IC₅₀=0.164 mg/mL). The increase in postprandial blood glucose levels was more significantly alleviated in the *G. procumbens* extract group than in the control group of STZ-induced diabetic mice. Moreover, the area under the curve significantly decreased with *G. procumbens* extract administration in STZ-induced diabetic mice. These results suggest that *G. procumbens* extract may help alleviate postprandial hyperglycemia by inhibiting carbohydrate digesting enzymes.

**Keywords:** *Gynura procumbens* extract, α-glucosidase, α-amylase, postprandial hyperglycemia

**INTRODUCTION**

Diabetes mellitus is a common endocrine system disorder that involves metabolic dysfunction (1,2). In diabetes, a rapid increase in blood glucose levels appears in the postprandial phase. Postprandial hyperglycemia is strongly related to the development of type 2 diabetes and diabetic complications, such as macrovascular and microvascular diseases (3). It has been reported that regulating postprandial hyperglycemia is more important than high fasting blood glucose levels (4). Postprandial hyperglycemia is also an independent risk factor for vascular diseases. Therefore, controlling postprandial hyperglycemia is essential for treating diabetic patients as well as the prevention of diabetic complications.

One of the most effective ways to lower postprandial hyperglycemia is by limiting the activities of carbohydrate-hydrolyzing enzymes in order to inhibit the entry of glucose into the intestinal endothelial cells (5). In humans, dietary starches are digested by the actions of pancreatic α-amylase and intestinal α-glucosidase to yield individual monosaccharides (6). Inhibitors of α-glucosidase are effective at suppressing postprandial hyperglycemia by limiting glucose absorption (7). Widely used as oral hypoglycemic agents, α-glucosidase inhibitors such as acarbose and voglibose directly reduce postprandial hyperglycemia and prevent vascular complications (8,9). However, long-term use of these drugs can lead to unwanted side effects, including vomiting, weight gain, and diarrhea (10,11). Thus, studies have focused on developing natural, plant-based inhibitors of α-glucosidase and α-amylase without side effects.

*Gynura procumbens* (Lour.) Merr. (*G. procumbens*) is a member of the Asteraceae family. It has received attention as a folk remedy for treating diabetes. It has been reported that *G. procumbens* extract (GPE) showed antihypertensive (12), antioxidant (13), and anti-inflammatory effects (14). It has also been shown that a combination of *Azadirachta indica* and *G. procumbens* extracts (ratio of 50 mg/kg *A. indica*: 112.5 mg/kg *G. procumbens*) has anti-hyperglycemic effects in alloxan-induced diabetic rats (15). However, there are no studies thus far showing the effects of GPE on alleviating postprandial hyperglycemia through the inhibition of carbohydrate digestive enzymes in a diabetic animal model. Diabetes is induced by streptozotocin (STZ), a glucosamine-nitrosourea compound derived from *Streptomyces achromogenes* that is used clinically as a chemotherapeutic agent in the treatment of pan...
creatic β cell carcinoma. STZ damages pancreatic β cells, resulting in hypoinsulinemia and hyperglycemia. Therefore, the purpose of this study was to examine the effects of GPE on blood glucose levels in normal and STZ-induced diabetic mice. In addition, we investigated the inhibitory effects of GPE on α-glucosidase and α-amylase, as well as the effects of GPE on postprandial hyperglycemia.

MATERIALS AND METHODS

Materials and preparation of GPE

G. procumbens was collected from Uiwang, Gyeonggi, Korea. The plant was washed with distilled water, freeze dried, and ground into a powder. The G. procumbens powder was then extracted 3 times with water for 12 h at room temperature. The GPE was concentrated in a rotary vacuum evaporator, freeze-dried to a powder, and then stored in a deep freezer (−80°C). All other chemicals and reagents, including α-glucosidase and α-amylase, were of analytical grade and were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). All chemicals and reagents were used without any further purification.

The total flavonoid content of GPE was 10.33±0.88 mg catechin equivalents (CE)/g dry weight (DW). GPE contained 464.53±1.81 μg/g DW of kaempferol, 251.10±3.67 μg/g DW of myricetin, and 135.87±0.40 μg/g DW of quercetin (16).

Inhibition of α-glucosidase activity by GPE in vitro

The α-glucosidase inhibition assay was conducted using a chromogenic method, as described by Watanabe et al. (17), with a readily available yeast enzyme. Briefly, yeast α-glucosidase (0.7 U; Sigma-Aldrich Co.) was dissolved in 100 mM phosphate buffer (pH 7.0) containing 2 g/L bovine serum albumin and 0.2 g/L NaNO3 and used as an enzyme solution. Five mM p-nitrophenyl-α-D-glucopyranoside (pNGP) in the same buffer (pH 7.0) was used as the substrate solution. Next, 50 μL of the enzyme solution and 10 μL of sample dissolved in dimethylsulfoxide (5 mg/mL) were mixed in each well of a microtiter plate, and the titer was measured by determining the absorbation at 405 nm at time 0 using a microplate reader. After incubation for 5 min, the substrate solution (50 μL) was added and incubated for another 5 min at room temperature. The increase in absorbance from time 0 was measured. The inhibitory activity was expressed as 100 minus the absorbance difference (%). The test compounds relative to the absorbance change of the control (the test solution was replaced by the carrier solvent).

Inhibition of α-amylase activity by GPE in vitro

The inhibitory activity of α-amylase was assayed in the same way as described for α-glucosidase inhibition, except that porcine pancreatic amylase (100 U) and p-nitrophenyl-α-D-maltopentoglycoside were used as the enzyme and substrate, respectively.

Measurement of cytotoxicity

Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 3T3-L1 mouse embryo fibroblasts were seeded at the concentration of 1×10^4 cells/well in 96 well plates and pre-incubated in a humidified atmosphere containing 5% CO2 at 37°C for 24 h. After that, the cells were treated with various concentrations (0.1, 0.5, 1, and 2 mg/mL) of GPE, and further incubated for 24 h. After completion of the treatment, the cells were incubated for 3 h at 37°C with filtered MTT (Sigma-Aldrich Co.) solution, which was added to each well to reach a final concentration of 0.5 mg MTT/mL. The supernatants were carefully aspirated, 200 μL of dimethyl sulfoxide was added to each well, and the plates were agitated to dissolve the crystal product. The absorbance was measured at 540 nm with a microplate reader.

Experimental animals

Male ICR mice (aged 4 weeks; purchased from Joong Ang Lab Animal Co., Seoul, Korea) were used. All animals were housed individually in a room with controlled light (12-h on/12-h off) and temperature, and pelleted food and water were available ad libitum. A meta analysis of 2 weeks, diabetes was induced by intraperitoneal (i.p.) injection of 60 mg/kg STZ freshly dissolved in a citrate buffer (0.1 M, pH 4.5). After 7 days, tail bleeds were performed and animals with a blood glucose concentration above 250 mg/dL were considered diabetic. All procedures for handling and care of animals were approved by the animal ethics committee at Pusan National University (PNU2014-0619).

Measurement of blood glucose levels

Normal mice and STZ-induced diabetic mice were fasted overnight and randomly divided into 3 groups (n=7 mice each). Fasted animals were deprived of food for at least 12 h, but allowed free access to water. After overnight fasting, the mice were orally administered soluble starch [2 g/kg body weight (bw)] alone, with GPE (300 mg/kg bw), or with acarbose (100 mg/kg bw). Blood samples were taken from the tail vein at 0, 30, 60, and 120 min (18). Blood glucose was measured using a glucometer (Roche Diagnostics Deutschland GmbH, Mannheim, Germany). The areas under the curve (AUC) were calculated using the trapezoidal rule.

Data and statistical analysis

The data are presented as the mean±standard deviation.
Anti-Hyperglycemic Effect of Gynura procumbens

Fig. 1. Inhibitory effects of Gynura procumbens extract on \( \alpha \)-glucosidase. Inhibitory effect was determined using \( p \)-nitrophenyl-\( \alpha \)-D-glucopyranoside as the substrate. Acarbose was used as a positive control. Each value is expressed as the mean ±SD of triplicate experiments. Values with different letters (a-c) are significantly different at \( P<0.05 \) as analyzed by Duncan’s multiple range tests.

RESULTS AND DISCUSSION

Inhibitory effect of GPE on \( \alpha \)-glucosidase and \( \alpha \)-amylase in vitro

The inhibitory effects of GPE against \( \alpha \)-glucosidase were examined using \( p \)-NPG as the substrates and were compared to that of the commercial \( \alpha \)-glucosidase inhibitor acarbose (Fig. 1). The activity of \( \alpha \)-glucosidase was inhibited by GPE in a concentration-dependent manner, with 36.88±7.35, 52.58±5.28, 63.78±3.08, and 75.81±3.31% inhibition at concentrations of 0.05, 0.1, 0.25, and 0.50 mg/mL, respectively. Acarbose, an \( \alpha \)-glucosidase inhibitor used as an oral hypoglycemic agent, inhibited the enzyme activity by 68.22% at a concentration of 0.10 mg/mL. The inhibitory effects of GPE on \( \alpha \)-amylase activity were determined in a similar manner (Fig. 2). The inhibitory effects of GPE against \( \alpha \)-amylase increased in a concentration-dependent manner (40.21±6.55, 54.33±8.05, 67.75±4.42, and 78.53±3.15% activity inhibition at concentrations of 0.05, 0.1, 0.25, and 0.50 mg/mL, respectively). Moreover, the inhibitory effects of GPE were more effective than that of acarbose even at the low concentration (0.10 mg/mL). The \( IC_{50} \) values of GPE against \( \alpha \)-glucosidase and \( \alpha \)-amylase were 0.092±0.018 and 0.084±0.027 mg/mL, respectively (Table 1). These results indicate that GPE may prove useful as a natural anti-hyperglycemic material by inhibiting \( \alpha \)-glucosidase and \( \alpha \)-amylase.

One effective method for controlling postprandial hyperglycemia is to inhibit carbohydrate hydrolyzing enzymes (intestinal \( \alpha \)-glucosidase and pancreatic \( \alpha \)-amylase) in order to slow down glucose absorption (18). Alpha-amylase begins the process by catalyzing the hydrolysis of polysaccharide \( \alpha \)-1,4-glycosidic linkages, forming disaccharides; \( \alpha \)-amylase further catalyzes the breakdown of disaccharides into simple sugars, which are available for absorption by intestinal cells (19,20). The inhibition of \( \alpha \)-glucosidase and \( \alpha \)-amylase activity might be an effective way to delay carbohydrate digestion and lower postprandial hyperglycemia. Therefore, identification of effective carbohydrate-hydrolyzing inhibitors from natural products to alleviate postprandial hyperglycemia without unwanted secondary effects is necessary (21).

This study was designed to investigate the inhibitory activities of GPE against \( \alpha \)-glucosidase and \( \alpha \)-amylase in an attempt to identify its efficacy as a natural product to alleviate postprandial hyperglycemia. GPE showed noticeable inhibition of both \( \alpha \)-glucosidase and \( \alpha \)-amylase activities, and it did not exert any cytotoxicity (Fig. 3).
GPE contains various kinds of flavonoids, such as kaempferol, myricetin, and quercetin. Flavonoids have been reported to inhibit α-glucosidase and α-amylase activities (22). These flavonoids may inhibit the α-glucosidase and α-amylase activities by influencing their hydrophobic and hydrophilic properties at a molecular level (23). Tadera et al. (7) reported that hydroxyl substitution on the phenyl ring structure of myricetin might be effective in inhibiting the enzyme’s activity. Additionally, kaempferol-3-O-glycoside has remarkable α-glucosidase inhibition ability (24). Therefore, it is possible that the flavonoids contained in GPE play a role in the inhibitory effects on α-glucosidase and α-amylase.

Effects of GPE on blood glucose levels in vivo
The effects of GPE on blood glucose levels following a meal were investigated in normal and STZ-induced diabetic mice. Postprandial blood glucose levels in mice administered GPE were significantly lower than those of the control diabetic mice (Fig. 4). Blood glucose levels in the control diabetic mice increased to 391.00±28.35 at 30 min and 414.40±26.19 mg/dL at 60 min after a meal, and then decreased to 374.00±24.47 mg/dL at 120 min. However, when GPE was added to the food, the increase in postprandial blood glucose levels was significantly alleviated (374.01±16.61, 385.50±14.57, and 330.67±16.10 mg/dL at 30, 60, and 120 min, respectively; P<0.05). Postprandial blood glucose levels also significantly decreased when normal mice were orally administered starch combined with GPE (Fig. 5; P<0.05). Collectively, the increase in postprandial blood glucose levels was suppressed significantly in both STZ-induced diabetic and normal mice treated with GPE.

The AUC for the glucose response in diabetic mice administered GPE (723.13±28.67 mg·h/dL) was significantly lower (P<0.05) than that in diabetic control mice (765.85±52.20 mg·h/dL; Table 2). The AUCs in normal mice were consistent with those in diabetic mice. Postprandial blood glucose levels in mice administered GPE were significantly lower than those of the control diabetic mice (Fig. 4). Blood glucose levels in the control diabetic mice increased to 391.00±28.35 at 30 min and 414.40±26.19 mg/dL at 60 min after a meal, and then decreased to 374.00±24.47 mg/dL at 120 min. However, when GPE was added to the food, the increase in postprandial blood glucose levels was significantly alleviated (374.01±16.61, 385.50±14.57, and 330.67±16.10 mg/dL at 30, 60, and 120 min, respectively; P<0.05). Postprandial blood glucose levels also significantly decreased when normal mice were orally administered starch combined with GPE (Fig. 5; P<0.05). Collectively, the increase in postprandial blood glucose levels was suppressed significantly in both STZ-induced diabetic and normal mice treated with GPE. The AUC for the glucose response in diabetic mice administered GPE (723.13±28.67 mg·h/dL) was significantly lower (P<0.05) than that in diabetic control mice (765.85±52.20 mg·h/dL; Table 2). The AUCs in normal mice were consistent with those in diabetic mice. Postprandial blood glucose levels in mice administered GPE were significantly lower than those of the control diabetic mice (Fig. 4). Blood glucose levels in the control diabetic mice increased to 391.00±28.35 at 30 min and 414.40±26.19 mg/dL at 60 min after a meal, and then decreased to 374.00±24.47 mg/dL at 120 min. However, when GPE was added to the food, the increase in postprandial blood glucose levels was significantly alleviated (374.01±16.61, 385.50±14.57, and 330.67±16.10 mg/dL at 30, 60, and 120 min, respectively; P<0.05). Postprandial blood glucose levels also significantly decreased when normal mice were orally administered starch combined with GPE (Fig. 5; P<0.05). Collectively, the increase in postprandial blood glucose levels was suppressed significantly in both STZ-induced diabetic and normal mice treated with GPE. The AUC for the glucose response in diabetic mice administered GPE (723.13±28.67 mg·h/dL) was significantly lower (P<0.05) than that in diabetic control mice (765.85±52.20 mg·h/dL; Table 2). The AUCs in normal mice were consistent with those in diabetic mice.
that in diabetic mice, demonstrating the anti-postprandial hyperglycemic effects of GPE.

Maintaining near normal blood glucose levels in both fasting and postprandial states is important for diabetic patients. It is well known that postprandial hyperglycemia is a major factor in the development of type 2 diabetes, and it is associated with diabetic complications (25, 26). Prolonged postprandial hyperglycemia may lead to the generation of oxidative stress, which can trigger inflammation and endothelial dysfunction, as well as diabetic complications, such as microvascular and macrovascular disease. Thus, alleviating postprandial hyperglycemia is crucial for the prevention and treatment of type 2 diabetes (27,28).

As shown in Fig. 3 and Fig. 4, postprandial hyperglycemia was significantly alleviated following the consumption of GPE-supplemented starch in both STZ-induced diabetic mice and normal mice. This may be due to the inhibition of carbohydrate hydrolyzing enzyme (pancreatic α-amylase and intestinal α-glucosidase) activities by GPE, thereby delaying the absorption of dietary carbohydrates in the small intestine epithelial cells. Chemicals that flatten the peak of postprandial hyperglycemia reduce the area under the blood glucose response curve (29). In this study, GPE reduced the peak of postprandial hyperglycemia and the AUC. These results also suggest that GPE may help alleviate postprandial hyperglycemia.

Alleviating postprandial hyperglycemia is important for the treatment of diabetic symptoms. Various synthetic compounds have been used in diabetes therapy. However, these products have usually been associated with unwanted side effects (30). Hence, many studies have tried to find natural resources that can alleviate postprandial hyperglycemia. The current study suggests that GPE might be effective for alleviating postprandial hyperglycemia and preventing diabetic complications. In conclusion, the results of this study showed that GPE has significant inhibitory effects on α-glucosidase and α-amylase activities. Furthermore, GPE likely alleviates postprandial hyperglycemia. Thus, GPE may be used as a functional food to alleviate postprandial hyperglycemia.

**REFERENCES**

1. Kim JS, Yang J, Kim MJ. 2011. Alpha glucosidase inhibitory effect, anti-microbial activity and UPLC analysis of Rhus verniciflua under various extract conditions. *J Med Plants Res* 5: 778-783.
2. Palanuvej C, Hokputsa S, Tunsaringkarn T, Ruangrungsri N. 2009. *In vitro* glucose entrapment and alpha-glucosidase inhibition of mucilaginous substances from selected Thai medicinal plants. *Sci Pharm* 77: 837-849.
3. Baron AD. 1998. Postprandial hyperglycaemia and alpha-glucosidase inhibitors. *Diabetes Res Clin Pract* 40: S51-S55.
4. Ceriello A. 2005. Postprandial hyperglycaemia and diabetes complications: is it time to treat? *Diabetes* 54: 1-7.
5. Lee BH, Eskandari R, Jones K, Reddy KR, Quezada-Calvillo R, Nichols BL, Rose DR, Hamaker BR, Pinto BM. 2012. Modulation of starch digestion for slow glucose release through “toggling” of activities of mucosal α-glucosidases. *J Biol Chem* 287: 31929-31938.
6. Jo SH, Ha KS, Moon KS, Lee OH, Jang HD, Kwon YI. 2011. *In vitro* and *in vivo* anti-hyperglycemic effects of Omija (*Schizandra chinensis*) fruit. *Int J Mol Sci* 12: 1359-1370.
7. Tadera K, Minami Y, Takamatsu K, Matsuoka T. 2006. Inhibition of α-glucosidase and α-amylase by flavonoids. *J Nutr Sci Vitaminol* 52: 149-153.
8. He K, Shi JC, Mao XM. 2014. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. *Ther Clin Risk Manag* 10: 505-511.
9. Derosa G, Maffioli P. 2012. α-Glucosidase inhibitors and their use in clinical practice. *Arch Med Sci* 8: 899-906.
10. Joshi SR, Ramachandran A, Chadha M, Chatterjee S, Rathod R, Kalra S. 2014. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes. *Expert Opin Pharmacother* 15: 1611-1620.
11. Katahira H, Ishida H. 2002. Indication and side effect of alpha glucosidase inhibitor. *Nihon Rinsho* 60: 399-408.
12. Kim MJ, Lee HJ, Wiryowidagdo S, Kim HK. 2007. Anti-hyperglycemic effects of *Gynura procumbens* extract in spontaneously hypertensive rats. *J Med Food* 9: 587-590.
13. Akowuah G, Ahmad M, Chin JH. 2009. The effect of extraction temperature on total phenols and antioxidant activity of *Gynura procumbens* leaf. *Pharmacogn Mag* 4: 81-85.
14. Iskander MN, Song Y, Coupar IM, Jiratchariyakul W. 2002. Antiinflammatory screening of the medicinal plant *Gynura procumbens*. *Plant Foods Hum Nutr* 57: 233-244.
15. Sunarwidi AL, Sudarsono S, Nugroho AE. 2014. Hypoglycemic effect of combination of *Azadirachta indica* A. Juss. and *Gynura procumbens* (Lour.) Merr. ethanolic extracts standardized by rutin and quercetin in alloxan-induced hyperglycemic rats. *Adv Pharm Bull* 4: 613-618.
16. Kaewseejan N, Suttikhum V, Siriamornpun S. 2015. Potential of *Gynura procumbens* leaves as source of flavonoid-enriched fractions with enhanced antioxidant capacity. *J Funct Foods* 12: 120-128.
17. Watanabe J, Kawabata J, Kurihara H, Niki R. 1997. Isolation and identification of α-glucosidase inhibitors from tochu-cha (*Eucommia ulmoides*). *Biosci Biotechnol Biochem* 61: 177-178.
18. Abid S, Lekchiri A, Mekfi H, Ziyaya A, Leggysyer A, Aziz M, Bnouhm A. 2014. Inhibition of α-glucosidase and glucose intestinal absorption by *Thymelaea hirsuta* fractions. *J Diabetes* 6: 351-359.
19. Haru Y, Honda M. 1990. The inhibition of α-amylase by tea polyphenols. *Agric Biol Chem* 54: 1939-1945.
20. Matsui T, Tanaka T, Tamura S, Toshima A, Tamaya K, Miyata Y, Tanaka K, Matsumoto K. 2007. α-Glucosidase inhibitory profile of catechins and theaflavins. *J Agric Food Chem* 55: 99-105.
21. Hadrich F, Boulaghlagi Z, Junkyu H, Isoda H, Sayadi S. 2015. The α-glucosidase and α-amylase enzyme inhibitory of hydroxytyrosol and oleuropein, *J Oleo Sci* 64: 835-843.
22. Yang G, Shu XO, Jin F, Elasy T, Li HL, Li Q, Huang F, Zhang XL, Gao YT, Zheng W. 2004. Soyfood consumption and risk of glycosuria: a cross-sectional study within the Shanghai Women's Health Study. *Eur J Clin Nutr* 58: 615-620.

**AUTHOR DISCLOSURE STATEMENT**

The authors declare no conflict of interest.

**REFERENCES**

1. Kim JS, Yang J, Kim MJ. 2011. Alpha glucosidase inhibitory effect, anti-microbial activity and UPLC analysis of *Rhus verniciflua* under various extract conditions. *J Med Plants Res* 5: 778-783.
2. Palanuvej C, Hokputsa S, Tunsaringkarn T, Ruangrungsri N.
23. Wang Y, Ma L, Li Z, Du Z, Liu Z, Qin J, Wang X, Huang Z, Gu L, Chen AS. 2004. Synergetic inhibition of metal ions and genistein on α-glucosidase. FEBS Lett 576: 46-50.
24. Hong HC, Li SL, Zhang XQ, Ye WC, Zhang QW. 2013. Flavonoids with α-glucosidase inhibitory activities and their contents in the leaves of Morus atropurpurea. Chin Med 8: 19.
25. Koskinen P, Määttäri M, Manninen V, Huttunen JK, Heino nen OP, Frick MH. 1992. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15: 820-825.
26. Vergès BL. 1999. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequen ces on the development of atherogenesis. Diabetes Metab 25: 32-40.
27. Lorber D. 2014. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 7: 169-183.
28. Ceriello A. 2004. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J 147: 803-807.
29. Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. 1997. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 36: 143-151.
30. Yale JF. 2005. Oral antihyperglycemic agents and renal dis ease: new agents, new concepts. J Am Soc Nephrol 16: S7-S10.